Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update [Yahoo! Finance]
Alpha Cognition Inc. (ACOG)
Company Research
Source: Yahoo! Finance
biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended September 30, 2024, and provided a corporate update. "The FDA approval of ZUNVEYL represents an important breakthrough for patients with Alzheimer's disease. Alpha Cognition is focused on commercial preparation in the US market and ex-US licensing opportunities to bring this important therapy to market. The team is adding important expertise in marketing, sales, product reimbursement, and medical to bring ZUNVEYL to patients in Q1, 2025" said Michael McFadden, the Company's Chief Executive Officer. Third Quarter 2024 Business Accomplishments and Corporate Highlights The Company raised $4.5M gross proceeds in a bridge financing. Use of proceeds will be to build commercial supply and prepare for commercialization. Manufacturing stability tests were successful, which will extend the commercial shelf life
Show less
Read more
Impact Snapshot
Event Time:
ACOG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACOG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACOG alerts
High impacting Alpha Cognition Inc. news events
Weekly update
A roundup of the hottest topics
ACOG
News
- Alpha Cognition Announces Partial Exercise of Over-allotment Option [Yahoo! Finance]Yahoo! Finance
- Alpha Cognition Announces Partial Exercise of Over-allotment OptionBusiness Wire
- Alpha Cognition Announces Voluntary Delisting from CSEBusiness Wire
- Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury [Yahoo! Finance]Yahoo! Finance
- Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain InjuryBusiness Wire
ACOG
Sec Filings
- 12/20/24 - Form 8-K
- 11/18/24 - Form 8-K
- 11/18/24 - Form D
- ACOG's page on the SEC website